Trade Summary

3 days ago, Evans John M., serving as CEO at Beam Therapeutics Inc. (BEAM), sold 50,000 shares at $34.90 per share, for a total transaction value of $1,745,037.20. Following this transaction, Evans John M. now holds 1,047,205 shares of BEAM.

This sale represents a 4.56% decrease in Evans John M.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, June 29, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, July 1, 2026 at 4:05 PM ET, 2 days after the trade was made.

Beam Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.